Anúncio
Anúncio

TELO

TELO logo

Telomir Pharmaceuticals, Inc. Common Stock

1.43
USD
Patrocinado
-0.04
-2.73%
08 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

1.44

+0.01
+0.70%

Relatórios de Lucros TELO

Rácio de surpresa positiva

TELO separação 2 de 4 últimas estimativas.

50%

Próximo Relatório

Data do Próximo Relatório
02 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.07
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
+133.33%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
-22.22%

Telomir Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On 10 de nov. de 2025, TELO reported earnings of -0.03 USD per share (EPS) for Q3 25, beating the estimate of -0.07 USD, resulting in a 57.98% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +3.65% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analistas forecast an EPS of -0.07 USD, with revenue projected to reach -- USD, implying an aumentar of 133.33% EPS, and aumentar of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Pharmaceuticals Inc. Common
Report Date
26 de dez. de 2025 Para Q4 25
Estimativa
-$0.49
Real
-
Surpresa
-
FAQ
For Q3 2025, Telomir Pharmaceuticals, Inc. Common Stock reported EPS of -$0.03, beating estimates by 57.98%, and revenue of $0.00, 0% as expectations.
The stock price moved up 3.65%, changed from $1.37 before the earnings release to $1.42 the day after.
The next earning report is scheduled for 02 de fev. de 2026.
Based on 3 analistas, Telomir Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of -- for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio